FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

MeiraGTx Holdings plc MGTX

Promising (early)   broader-coverage candidate · MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses.

On FrontierLab's discovery record since 2026-08-06 (2 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-08), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)131.1%
Gross margin91.6%
Gross profits / assets0.3
Rule of 40-0.8
Net margin-131.9%
Cash runway (months)
PEG
Price / sales15.2

Quality checklist

Fundamentals — snapshot as of 2026-08-08

StageEarly
Share issuance (YoY)2.9% · modest issuance
Moat
TAM
P/E (trailing)
EPS (trailing)$-1.48
Burn multiple
Gross-margin trend (pts)64.5
Cash / assets0.29
Net debt / EBITDA
Statements as ofQ1 FY2026 · filed 2026-05-14

Momentum context — a snapshot from 2026-08-08, not current

Price at surface$13.07 (as of 2026-08-08)
52-week range$6.62 – $15.35
% off 52-wk high-14.9%
RSI (14)60
Relative volume0.5×

Risk flags

Burning cash — operating margin is negative.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-08 (end-of-day). How grades are computed →